Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent Results of a phase III multicenter trial11Principal Investigators for the OPTISON Multicenter Trial: David S. Bach, MD, University of Michigan Medical Center, Ann Arbor, MI; Jorge Cheirif, MD, Ochsner Heart and Vascular Institute, New Orleans, LA; Jerald L. Cohen, MD, New Jersey VA Medical Center, East Orange, NJ; Linda J. Crouse, MD, Mid-America Cardiology Associates, Kansas City, MO; John Dent, MD, University of Virginia Medical Center, Charlottesville, VA; Candace Dick, MD, Hennipin County Medical Center, Minneapolis, MN; Samer Ellahham, MD,